A detailed history of Advisory Services Network, LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Advisory Services Network, LLC holds 11,800 shares of SAVA stock, worth $31,388. This represents 0.01% of its overall portfolio holdings.

Number of Shares
11,800
Previous 11,800 -0.0%
Holding current value
$31,388
Previous $145,000 139.31%
% of portfolio
0.01%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$12.35 - $26.11 $264,290 - $558,754
-21,400 Reduced 64.46%
11,800 $145,000
Q1 2024

May 06, 2024

BUY
$18.44 - $26.41 $355,707 - $509,448
19,290 Added 138.68%
33,200 $673,000
Q4 2023

Feb 09, 2024

SELL
$12.64 - $30.11 $70,657 - $168,314
-5,590 Reduced 28.67%
13,910 $313,000
Q3 2023

Nov 14, 2023

SELL
$16.64 - $25.32 $6,656 - $10,128
-400 Reduced 2.01%
19,500 $324,000
Q2 2023

Aug 09, 2023

SELL
$21.59 - $27.88 $11,960 - $15,445
-554 Reduced 2.71%
19,900 $487,000
Q1 2023

May 17, 2023

BUY
$23.46 - $36.44 $225,216 - $349,824
9,600 Added 88.45%
20,454 $493,000
Q4 2022

Feb 13, 2023

BUY
$27.82 - $44.16 $161,356 - $256,127
5,800 Added 114.76%
10,854 $320,000
Q3 2022

Nov 14, 2022

SELL
$16.33 - $51.06 $18,371 - $57,442
-1,125 Reduced 18.21%
5,054 $211,000
Q2 2022

Aug 02, 2022

BUY
$17.22 - $38.47 $3,530 - $7,886
205 Added 3.43%
6,179 $174,000
Q1 2022

May 23, 2022

SELL
$32.6 - $53.05 $332,552 - $541,163
-10,201 Reduced 63.07%
5,974 $222,000
Q4 2021

Feb 14, 2022

BUY
$36.77 - $90.91 $542,798 - $1.34 Million
14,762 Added 1044.73%
16,175 $707,000
Q3 2021

Nov 05, 2021

BUY
$41.79 - $135.3 $59,049 - $191,178
1,413 New
1,413 $88,000
Q4 2020

Feb 09, 2021

SELL
$6.79 - $12.25 $4,481 - $8,085
-660 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$2.86 - $11.51 $1,887 - $7,596
660 New
660 $8,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $107M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Advisory Services Network, LLC Portfolio

Follow Advisory Services Network, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisory Services Network, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Advisory Services Network, LLC with notifications on news.